ATE264099T1 - Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen - Google Patents

Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen

Info

Publication number
ATE264099T1
ATE264099T1 AT94918217T AT94918217T ATE264099T1 AT E264099 T1 ATE264099 T1 AT E264099T1 AT 94918217 T AT94918217 T AT 94918217T AT 94918217 T AT94918217 T AT 94918217T AT E264099 T1 ATE264099 T1 AT E264099T1
Authority
AT
Austria
Prior art keywords
treatment
methods
pharmaceutical compositions
compositions useful
neurological diseases
Prior art date
Application number
AT94918217T
Other languages
English (en)
Inventor
David John Kyle
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22114083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE264099(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Application granted granted Critical
Publication of ATE264099T1 publication Critical patent/ATE264099T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
AT94918217T 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen ATE264099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7350593A 1993-06-09 1993-06-09
PCT/US1994/006317 WO1994028913A1 (en) 1993-06-09 1994-06-02 Methods and pharmaceutical compositions useful for treating neurological disorders

Publications (1)

Publication Number Publication Date
ATE264099T1 true ATE264099T1 (de) 2004-04-15

Family

ID=22114083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075413T ATE446101T1 (de) 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
AT94918217T ATE264099T1 (de) 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04075413T ATE446101T1 (de) 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung

Country Status (11)

Country Link
EP (3) EP2140863A1 (de)
JP (3) JPH08511533A (de)
AT (2) ATE446101T1 (de)
AU (1) AU693450B2 (de)
CA (2) CA2164291C (de)
DE (2) DE69433713T2 (de)
DK (1) DK0707487T3 (de)
ES (2) ES2218525T3 (de)
MX (1) MX263227B (de)
PT (1) PT707487E (de)
WO (1) WO1994028913A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5583019A (en) 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
EP0823475B1 (de) * 1995-04-17 2009-06-17 National Institute of Advanced Industrial Science and Technology Hoch ungesättigte fettsäurenproduzierende mikroorganismen und verfahren zur herstellung von hoch ungesättigten fettsäuren durch verwendung dieser mikroorganismen
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
ES2267137T5 (es) * 1996-03-28 2014-03-14 Dsm Ip Assets B.V. Aceite microbiano que contiene ácido graso poli-insaturado y método de producir aceite a partir de biomasa pasteurizada y granulada
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6166230A (en) * 1996-05-15 2000-12-26 Gist-Brocades B.V. Sterol extraction with polar solvent to give low sterol, high triglyceride, microbial oil
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP3792309B2 (ja) * 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use
FR2782921B1 (fr) * 1998-09-09 2002-09-20 Dior Christian Parfums Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique
CN102090636A (zh) * 1998-10-15 2011-06-15 Dsm公司 Pufa增补剂
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
EP1178103A1 (de) 2000-08-02 2002-02-06 Dsm N.V. Reinigung von rohen PUFA-reichen Ölen
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
KR20180081845A (ko) 2002-06-19 2018-07-17 디에스엠 아이피 어셋츠 비.브이. 미생물 세포와 미생물 오일용 파스퇴르살균 방법
EP2295529B2 (de) 2002-07-11 2022-05-18 Basf As Verfahren zur Verminderung von Umweltschadstoffen in einem Öl oder einem Fett und Fischfutterprodukt
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
US20040092590A1 (en) 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
EP1551382A4 (de) 2002-09-27 2007-01-24 Martek Biosciences Corp Prophylaktische behandlung mit docosahexaensäure für patienten mit subklinischer entzündung
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006077495A1 (en) * 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases
EP1888081B1 (de) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Zusammensetzungen mit pufa und anwendungsverfahren dafür
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
FR2894772B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Procede d'enrichissement en dha
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
AU2006327064B2 (en) * 2005-12-21 2012-04-26 Brudy Technology, S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
CN101631542B (zh) 2006-12-28 2011-12-21 三得利控股株式会社 神经再生剂
DE102007031039A1 (de) * 2007-07-04 2009-01-08 Süd-Chemie AG Verfahren zur schonenden Raffination von Pflanzenölen mit Naturbleicherde
JP2012516852A (ja) * 2009-02-02 2012-07-26 マーテック バイオサイエンシーズ コーポレーション 認知機能改善および心拍数低下のための方法
EP4183883A1 (de) 2009-03-19 2023-05-24 DSM IP Assets B.V. Thraustochytride, fettsäurezusammensetzungen und verfahren zur herstellung und verwendungen davon
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
EP2576801B1 (de) * 2010-06-01 2019-10-02 DSM IP Assets B.V. Extraktion von lipiden aus zellen und produkte daraus
JP6025568B2 (ja) * 2010-12-28 2016-11-16 株式会社藤野ブレインリサーチ 認知症を血液サンプルで判定するための検査方法
EP2709611A4 (de) * 2011-05-19 2014-10-29 Univ California Therapeutische nahrung gegen kognitiven abbau
EA034980B1 (ru) * 2011-07-21 2020-04-14 ДСМ АйПи АССЕТС Б.В. Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции жирных кислот, способы их получения и применения
JP5496163B2 (ja) * 2011-10-19 2014-05-21 サントリーホールディングス株式会社 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
FR2991337B1 (fr) * 2012-05-29 2016-09-02 Roquette Freres Procede continu d'enrichissement en esters ethyliques de dha d'une huile produite par des microalgues
KR102615285B1 (ko) 2013-12-20 2023-12-19 마라 리뉴어블즈 코퍼레이션 미생물로부터 오일을 회수하는 방법
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CN110337430B (zh) 2016-11-17 2023-02-03 德布勒森大学 提供维生素a5途径的维甲类的前体化合物及其用途
KR101946362B1 (ko) * 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
AU2122688A (en) * 1987-07-20 1989-02-13 Maricultura, Incorporated Microorganism production of omega-3 (n-3) lipids
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5130242A (en) * 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
JP2730081B2 (ja) * 1988-09-24 1998-03-25 日本油脂株式会社 微生物によるアラキドン酸含有油脂の製造方法
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
CA2101274C (en) * 1991-01-24 1998-12-15 David J. Kyle Microbial oil mixtures and uses thereof
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2121986A1 (en) * 1993-04-26 1994-10-27 Daizo Takeuchi Processes for culturing marine microalgae and producing docosahexaenoic acid using the same

Also Published As

Publication number Publication date
EP0707487A1 (de) 1996-04-24
EP0707487B1 (de) 2004-04-14
PT707487E (pt) 2004-08-31
JP2011121978A (ja) 2011-06-23
CA2164291C (en) 2007-10-30
AU693450B2 (en) 1998-07-02
DE69433713D1 (de) 2004-05-19
JPH08511533A (ja) 1996-12-03
CA2596241A1 (en) 1994-12-22
AU6963594A (en) 1995-01-03
JP2008133286A (ja) 2008-06-12
ATE446101T1 (de) 2009-11-15
ES2335991T3 (es) 2010-04-07
DE69433713T2 (de) 2005-04-07
WO1994028913A1 (en) 1994-12-22
DK0707487T3 (da) 2004-08-02
EP1419780A1 (de) 2004-05-19
EP0707487A4 (de) 1998-09-02
CA2164291A1 (en) 1994-12-22
MX263227B (en) 2008-12-17
DE69435246D1 (de) 2009-12-03
EP1419780B1 (de) 2009-10-21
ES2218525T3 (es) 2004-11-16
EP2140863A1 (de) 2010-01-06
CA2596241C (en) 2011-04-19

Similar Documents

Publication Publication Date Title
DE69433713D1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
ATE210979T1 (de) Verwendung rapamycin zur herstellung eines medikaments für die verbeugung und behandlung von hyperproliferativen gefässerkrankheiten, eventuell in kombination mit mycophenolsäure
DE69334294D1 (de) Antikörper für die Behandlung von einer Immunerkrankung
WO1996040106A3 (en) Methods for controlling highly unsaturated fatty acid content in various tissues
DE69110561D1 (de) Mittel zur Behandlung und Vorbeugung von Bauchentzündungen, die als Wirkstoff Zink-L-Carnosin-Salze oder -Komplexe enthalten.
ATE238799T1 (de) Verfahren und mittel zur arzneistoffverabreichung
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
ATE156704T1 (de) Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
ATE290867T1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
GB9519661D0 (en) Fatty acid treatment
ATE227520T1 (de) Ernährungszusammensetzung
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
IL86862A (en) Pharmaceutical compositions for reducing the level of circulating immune complexes in vivo, containing mismatched double-stranded rna
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
TR199801043T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0707487

Country of ref document: EP

REN Ceased due to non-payment of the annual fee